Synakis Corp
Synakis Corp
01/06/2025 | Press release | Archived content
Research on Long-acting Glaucoma Treatment Published in Advanced Materials
Research on Long-acting Glaucoma Treatment Published in Advanced Materials
January 6, 2025
Research completed by Synakis' Mickael Dang, Molly Shoichet, and co-authors on a long-acting treatment for glaucoma has been published in Advanced Materials.
Dang et al. developed the treatment by embedding drug-rich nanoparticles called colloidal drug aggregates (CDAs) into Synakis' ocular biomaterial to enable long-acting controlled release of timolol-a beta-blocker used to lower intraocular pressure (IOP) in glaucoma patients. Non-invasive administration of the formulation into the subconjunctival space of rodent eyes enabled a prolonged IOP-lowering effect for up to 8 weeks.
This research is the basis of Synakis' pipeline product SNK-225 for the treatment of glaucoma.
Synakis Corp published this content on January 06, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on October 02, 2026 at 06:17 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]